July 27, 2017—As part of a government-wide deregulatory push, the Trump administration has ditched plans to publish dispute resolution regulations for the 340B drug discount program and to publish guidelines for much of the rest of the program. The head of the 340B program’s parent agency, however, recently told the hospital association 340B Health and members of the 340B Coalition that the agency’s 340B program ceiling price and manufacturer civil monetary penalties regulation remains on track to take effect on Oct. 1.
You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register. Already registered? Click here to login. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)